Abstract 2271
Background
No previous study has evaluated the prognostic value of coagulation factors in patients with early-stage natural killer/T-cell lymphoma (NKTCL). The aim of this study was to investigate the relationships between coagulation function and clinical response and prognosis in patients with early-stage NKTCL.
Methods
The data of patients with stage I/II NKTCL who were treated in Cancer Hospital, Chinese Academy of Medical Sciences from January 2008 to January 2019 were collected and studied retrospectively. Data included patients’ clinical characteristics and related indexes of coagulation function before treatment (preoperative activated partial thromboplastin time (APTT), prothrombin time (PT), prothrombin time activity (PTA), fibrinogen (FIB), international normalized ratio (INR), D-dimer, and platelet count (PLT)). The cut-off value was set as the median of pretreatment coagulation factors.
Results
A total of 159 patients with stage I/II NKTCL were included in this study. Abnormal coagulation function was found in nearly half of (49.69%) patients, and increased D-dimer(16.28%) and FIB(11.25%) were the most common abnormalities. Univariate analysis showed that increased D-dimer level (P < 0.001) and increased FIB level (P = 0.021) reduced complete remission (CR) rate. In addition to other prognostic factors including Eastern cooperative oncology group (ECOG) score≥2, B symptom, increased lactate dehydrogenase (LDH) level, increased D-dimer level was also demonstrated to be associated with the unfavorable progression-free survival (PFS) (P = 0.003) and overall survival (OS) (P = 0.002). Multivariate analysis indicated that increased D-dimer level was an independent factor for poor clinical response (P = 0.008), PFS (P = 0.021) and OS (P = 0.007).
Conclusions
Our study suggested that elevated pretreatment coagulation factors especially D-dimer and plasma FIB were unfavorable predictors for clinical response, OS and PFS in early-stage NKTCL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dong Mei.
Funding
The Cancer Foundation of China, Beijing Hope Marathon Project Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3309 - Heat Shock Protein 90 chaperones and Protein Kinase D3 regulates androgen-independent prostate cancer development
Presenter: Attila Varga
Session: Poster Display session 1
Resources:
Abstract
3441 - The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent
Presenter: Katia Ruggero
Session: Poster Display session 1
Resources:
Abstract
1659 - IGF1R inhibition affects the survival of HT29 cancer cells by alterations of the TLR9- and autophagy signaling
Presenter: Györgyi Műzes
Session: Poster Display session 1
Resources:
Abstract
1379 - Characterization of atypical dMMR (deficient MisMatch Repair) tumors: a study from a large cohort of 4948 cases
Presenter: Marion Jaffrelot
Session: Poster Display session 1
Resources:
Abstract
1657 - Modulation of TLR9-dependent autophagy response via inhibition of c-Met signaling influences the survival of HT29 cancer cells
Presenter: Ferenc Sipos
Session: Poster Display session 1
Resources:
Abstract
3045 - Positive Feedback Activation of Notch Signal by Obesity Enhances Colorectal Tumorigenicity
Presenter: Dake Chu
Session: Poster Display session 1
Resources:
Abstract
2285 - The Pathological and Functional Roles of BRPF1 in Hepatocellular Carcinoma
Presenter: Lai Hung Carol Cheng
Session: Poster Display session 1
Resources:
Abstract
3210 - Protein tyrosine phosphatase non-receptor type 3 (PTPN3) could be a new therapeutic target for pancreatic cancer.
Presenter: Akio Yamasaki
Session: Poster Display session 1
Resources:
Abstract
3920 - A Novel bispecific BCMAxCD3 T cell engaging antibody that treat multiple myeloma (MM) with minimal cytokine serection
Presenter: Zhenyu Li
Session: Poster Display session 1
Resources:
Abstract
2691 - Quantitative spatial profiling of lymphocyte-activation gene 3 (LAG-3)/major histocompatibility complex class II (MHC II) interaction in gastric and urothelial tumors
Presenter: Cyrus Hedvat
Session: Poster Display session 1
Resources:
Abstract